Anzeige
Mehr »
Login
Donnerstag, 26.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Während die Wall Street über Krypto-ETFs debattiert, liefert dieses Unternehmen 1.000?% RENDITE!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Actusnews Wire
807 Leser
Artikel bewerten:
(2)

BOIRON: Sales in the third quarter of 2023

Finanznachrichten News

(Unaudited data)

SALES IN THE THIRD QUARTER (VARIATION AT CURRENT EXCHANGE RATES)

In thousands of euros1st quarter2nd quarter3rd quarter
20232022Var.20232022Var.20232022Var.
France54,58077,055-29.2%52,27754,283-3.7%56,00558,275-3.9%
Europe (excluding France)39,22034,476+13.8%23,65626,228-9.8%30,56135,744-14.5%
North America33,27928,944+15.0%24,14823,282+3.7%28,86129,107-0.8%
Other countries5,2205,305-1.6%7,5047,189+4.4%5,6835,295+7.3%
Group total132,299145,780-9.2%107,585110,982-3.1%121,110128,422-5.7%

In thousands of euros1st quarter2nd quarter3rd quarter
20232022Var.20232022Var.20232022Var.
Non-proprietary homeopathic medicines45,23445,516-0.6%42,23143,360-2.6%39,30541,081-4.3%
Homeopathic specialties79,85867,100+19.0%57,11154,816+4.2%71,70974,349-3.6%
Other health products7,20633,164-78.3%8,24312,806-35.6%10,09612,992-22.3%
Group total132,299145,780-9.2%107,585110,982-3.1%121,110128,422-5.7%

Sales in the third quarter of 2023 were down 5.7%. Adjusted for the decline in COVID test sales this comes to 2.8%, exclusively due to the drop-in exchange rates.

The 4.3% decline in non-proprietary homeopathic medicines is still mainly attributable to France.

Sales from homeopathic specialties fell 3.6%, due to lower sales of winter specialties following a warm September.

Sales of other healthcare products continued to decline, due to a decrease in COVID test sales in Europe, particularly in France.

This decline was partially offset by the launch of the CBD by Boiron® range in France, formulated using 98% natural-origin ingredients and comprising three products:

  • a cream gel that helps restore joint movement and comfort,
  • a gel (tube and roll-on) that helps to reduce tension and relax muscles.

CUMULATIVE SALES AS OF THE END OF SEPTEMBER 2023

In thousands of euros20232022Variation
at current
exchange rates
Variation
at constant
exchange rates
France162,862189,612-14.1%-14.1%
Europe (excluding France)93,43796,448-3.1%-0.8%
North America86,28781,334+6.1%+8.6%
Other countries18,40717,789+3.5%+3.9%
Group total360,994385,183-6.3%-5.2%

In thousands of euros20232022Variation
at current
exchange rates
Variation
at constant
exchange rates
Non-proprietary homeopathic medicines126,771129,957-2.5%-2.1%
Homeopathic specialties208,679196,265+6.3%+8.2%
Other health products25,54558,961-56.7%-56.5%
Group total360,994385,183-6.3%-5.2%

Total sales fell 6.3%, impacted by a challenging basis for comparison following significant COVID test sales in France in 2022. Excluding these tests, sales were up 3%.

This growth was achieved in all regions and was driven by sales of homeopathic specialties.

Outlook

The decline in COVID test sales is expected to result in lower revenues in 2023 than in 2022. Excluding test sales, revenues are expected to grow, depending on winter illnesses at the end of the year.

We continue to put all our energy and determination into ensuring that every patient in the world can take advantage of homeopathy and our others healthcare solutions, thereby supporting a more humane, efficient and sustainable healthcare system.

Laboratoires BOIRON

Our next update:January 25, 2024: at market close, publication of the sales for the year 2023.
Person responsible for financial information: Valérie Lorentz-Poinsot
Contact for financial information: Fabrice Rey
Investor relations: +33 (0) 4.37.41.84.01 - e-mail: boironfinances@boiron.fr
ISIN Code: FR0000061129 (BOI) - Bloomberg: BOI FP - Reuters: BOIR.PA
The group's financial information and the glossary are online at: www.boironfinance.com

------------------------
This publication embed "Actusnews SECURITY MASTER".
- SECURITY MASTER Key: yJlrY8ltZmudnpyaaZdsnJaXam1qx2WXZ2bGk2SZaMubnJ1nl2qWZsaVZnFjmWts
- Check this key: https://www.security-master-key.com.
------------------------
Full and original release in PDF format:
https://www.actusnews.com/documents_communiques/ACTUS-0-82466-boi-201023-ca-t3-23-gb.pdf

© Copyright Actusnews Wire
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
© 2023 Actusnews Wire
6 Richtige für 2025
Das Börsenjahr 2025 klopft schon an die Tür – und wie immer geht es um die Frage: Welche Aktien werden die großen Gewinner sein? Die Auswahl an Möglichkeiten ist riesig, doch nur ein paar echte Volltreffer stechen heraus.

Ob stabiler Dividenden-Lieferant, Tech-Pionier oder spekulative Wette im Krypto-Bereich – wir haben die Märkte für Sie ausgiebig durchforstet und präsentieren Ihnen 6 Unternehmen, die große Chancen auf außergewöhnliche Kurssteigerungen besitzen. Hier sind, speziell für Sie, Ihre „6 Richtigen“ für 2025.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche Unternehmen das Potenzial besitzen, im kommenden Jahr richtig durchzustarten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.